The DOI matches its Crossref record; 232 of the 232 references it cites were found in a registry or an index.
Treatment of Inflammatory Bowel Disease: A Comprehensive Review
Open accessAbstract
Inflammatory bowel disease (IBD), as a global disease, has attracted much research interest. Constant research has led to a better understanding of the disease condition and further promoted its management. We here reviewed the conventional and the novel drugs and therapies, as well as the potential ones, which have shown promise in preclinical studies and are likely to be effective future therapies. The conventional treatments aim at controlling symptoms through pharmacotherapy, including aminosalicylates, corticosteroids, immunomodulators, and biologics, with other general measures and/or surgical resection if necessary. However, a considerable fraction of patients do not respond to available treatments or lose response, which calls for new therapeutic strategies. Diverse therapeutic options are emerging, involving small molecules, apheresis therapy, improved intestinal microecology, cell therapy, and exosome therapy. In addition, patient education partly upgrades the efficacy of IBD treatment. Recent advances in the management of IBD have led to a paradigm shift in the treatment goals, from targeting symptom-free daily life to shooting for mucosal healing. In this review, the latest progress in IBD treatment is summarized to understand the advantages, pitfalls, and research prospects of different drugs and therapies and to provide a basis for the clinical decision and further research of IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–232 of 232
D’Haens, G. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13803 · Cited by 59
Ford, A. C., Khan, K. J., Sandborn, W. J., Hanauer, S. B., & Moayyedi, P. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.10.043 · Cited by 58
Yoshino, T., Nakase, H., Minami, N., Yamada, S., Matsuura, M., Yazumi, S., & Chiba, T. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.10.011 · Cited by 56
Tazi, J., Begon‐Pescia, C., Campos, N., Apolit, C., Garcel, A., & Scherrer, D. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.019 · Cited by 56
Thiopurine Prodrugs Mediate Immunosuppressive Effects by Interfering with Rac1 Protein Function
Shin, J., Wey, M., Umutesi, H. G., Sun, X., Simecka, J. W., & Heo, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.694422 · Cited by 53
Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy
Lowe, S. C., Sauk, J. S., Limketkai, B. N., & Kwaan, M. R. (2020) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-020-04832-y · Cited by 52
The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease
Naganuma, M., Fujii, T., & Watanabe, M. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0352-z · Cited by 49
Lamers, C. R., de Roos, N. M., & Witteman, B. J. M. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01435-4 · Cited by 45
Khan, N. H., Abbas, A. M., Williamson, A., & Balart, L. A. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2748-0 · Cited by 42
Tang, M. T., Keir, M. E., Erickson, R., Stefanich, E. G., Fuh, F. K., Ramirez‐Montagut, T., McBride, J., & Danilenko, D. M. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14631 · Cited by 42
Mirmiran, P., Moslehi, N., Morshedzadeh, N., Shivappa, N., Hébert, J. R., Farsi, F., & Daryani, N. E. (2019) · Nutrition Journal · doi:10.1186/s12937-019-0492-9 · Cited by 42
Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease
Gjuladin-Hellon, T., Gordon, M. A., Iheozor‐Ejiofor, Z., et al. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008414.pub3 · Cited by 42
Wong, U., & Cross, R. K. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1597053 · Cited by 41
Samborski, P., & Grzymislawski, M. B. (2015) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/44144 · Cited by 38
Nakase, H., Hirano, T., Wagatsuma, K., Ichimiya, T., Yamakawa, T., Yokoyama, Y., Hayashi, Y., Hirayama, D., Kazama, T., Yoshii, S., et al. (2020) · Digestive Endoscopy · doi:10.1111/den.13825 · Cited by 38
Antibiotics for induction and maintenance of remission in Crohn's disease
Townsend, C., Parker, C. E., MacDonald, J. K., Jairath, V., Feagan, B. G., & Khanna, R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012730 · Cited by 37
Novak, G., Stevens, T. W., van Viegen, T., Bossuyt, P. J., Štabuc, B., Jeyarajah, J., Zou, G., Gaemers, I. C., McKee, T. D., Fu, F., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15250 · Cited by 37
Hart, A. L., Ng, S. C., Watkins, J., Paridaens, K., Edwards, J. O., Fullarton, J. R., Sonderegger, Y. L. Y., Ghatnekar, O., & Ghosh, S. K. (2020) · Annals of Gastroenterology · doi:10.20524/aog.2020.0521 · Cited by 35
The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease
Haifer, C., Leong, R. W. L., & Paramsothy, S. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.009 · Cited by 35
Investigating cell therapy for inflammatory bowel disease
Okamoto, R., & Watanabe, M. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1177019 · Cited by 34
Snowden, J. A., Ansari, A. R., Sachchithanantham, S., Jackson, G., Thompson, N., Lobo, A., Sanderson, J. D., & Kazmi, M. A. (2014) · QJM · doi:10.1093/qjmed/hcu095 · Cited by 33
Corticosteroid therapy in ulcerative colitis: Clinical response and predictors
Li, J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i10.3005 · Cited by 33
Self-citationfor the CAPTAIN study Group, Naganuma, M., Yokoyama, Y., Motoya, S., Watanabe, K., Sawada, K., Hirai, F., Yamamoto, T., Hanai, H., Omori, T., et al. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01651-0 · Cited by 33
Tran, V., Shammas, R. M., Sauk, J. S., & Padua, D. M. (2019) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s150908 · Cited by 32
Ou, G., Bressler, B., Galorport, C., Lam, E., Ko, H. H., Enns, R., Telford, J., Schaffer, N., Lee, T., & Rosenfeld, G. (2018) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwy023 · Cited by 28
Tyrosine Kinase 2 Signalling Drives Pathogenic T cells in Colitis
Vries, L. C. S. D., Ghiboub, M., van Hamersveld, P. H. P., Welting, O., Verseijden, C., Bell, M. J., Rioja, I., Prinjha, R. K., Koelink, P. J., Strobl, B., et al. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa199 · Cited by 27
Mucosal Healing Is Associated With the Reduced Disabling Disease in Crohn's Disease
Huang, S., Li, L., Ben‐Horin, S., Mao, R., Lin, S., Qiu, Y., Feng, R., He, Y., Chen, B., Zeng, Z., et al. (2019) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000015 · Cited by 26
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes
Fiorino, G., Gilardi, D., & Danese, S. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16647935 · Cited by 23
Pinto, A. L. T., Chebli, L. A., Ribeiro, M. S., Pace, F. H. D. L., Moraes, J. P., do Amaral, F. J., Gaburri, P. D., de Souza, A. F. M., & Chebli, J. M. F. (2009) · PubMed · Cited by 17
Pabón‐Carrasco, M., Ramírez‐Baena, L., Vilar-Palomo, S., Castro-Méndez, A., García, R. M., & Rodríguez-Gallego, I. (2020) · Nutrients · doi:10.3390/nu12092628 · Cited by 16
Pugliese, D., Aratari, A., Festa, S., Ferraro, P. M., Monterubbianesi, R., Guidi, L., Scribano, M. L., Papi, C., & Armuzzi, A. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/4195968 · Cited by 15
OP21 ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients
Vermeire, S., Hébuterne, X., Napora, P., Wisniewska-Jarosinska, M., Kiss, G. G., Bourreille, A., Przemysław, Z., Nitcheu, J., Gineste, P., Steens, J.-M., et al. (2019) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy222.020 · Cited by 15
Cited by
Sic, A., Cvetkovic, K., Manchanda, E., & Knezevic, N. N. (2024) · Diseases · doi:10.3390/diseases12090220 · Cited by 65
Benameur, T., Porro, C., Twfieg, M.-E., Benameur, N., Panaro, M. A., Filannino, F. M., & Hasan, A. (2023) · Brain Sciences · doi:10.3390/brainsci13081226 · Cited by 60
“In the context of intestinal microbiota disorder, researchers have demonstrated some effective treatment methods for IBD through the improvement of intestinal microecology, including the use of prebiotics, probiotics, antibiotics, postbiotics, symbiotics, and FMT [140].”
BackgroundInfluentialLiu, W., Zhang, S., Dong, C., Lv, X., Zheng, X., Zhao, W., Jamali, M., Abedi, R., & Saedisomeolia, A. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-01002-2 · Cited by 9
Metadata
- Authors
- Cai, Z., Wang, S., & Li, J.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2021-12-20
- Volume
- 8
- Pages
- 765474-765474
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W4200161003
- Cited by
- 675
- References
- 232
- FWCI
- 44.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.